BioAtla to Participate in the 2022 BTIG Biotechnology Conference

Rhea-AI Summary

BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biotechnology company, announced its participation in the 2022 BTIG Biotechnology Conference. The fireside chat is scheduled for August 8, 2022, at 12:00 p.m. ET in New York, NY. BioAtla specializes in Conditionally Active Biologic (CAB) therapeutics for treating solid tumors, featuring products in Phase 2 clinical testing, including mecbotamab vedotin and ozuriftamab vedotin. The company holds more than 600 patents, enhancing its innovative CAB technology and product candidates.

SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat at the 2022 BTIG Biotechnology Conference, to be held in New York, NY Monday, August 8, 2022.

2022 BTIG Biotechnology Conference
Format: Fireside chat
Date: Monday, August 8, 2022
Time: 12:00 p.m. ET
Location: New York, NY

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.

About BioAtla, Inc.

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal antibody and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with more than 600 patents, more than 350 of which are issued. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing in the United States, mecbotamab vedotin, BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 1 stage CAB-CTLA-4 antibody, BA3071, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. To learn more about BioAtla, Inc. visit www.bioatla.com.

Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945

External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

FAQ

When is BioAtla participating in the 2022 BTIG Biotechnology Conference?

BioAtla will participate in the 2022 BTIG Biotechnology Conference on August 8, 2022.

What is the format of the BioAtla event at the BTIG Conference?

The event will be a fireside chat.

What time is the BioAtla chat scheduled for?

The fireside chat is set for 12:00 p.m. ET.

Where is the BTIG Biotechnology Conference taking place?

The conference is being held in New York, NY.

What is BioAtla's focus in biotechnology?

BioAtla focuses on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors.

How many patents does BioAtla hold for its technologies?

BioAtla holds more than 600 patents for its CAB technology and products.

Which BioAtla products are in Phase 2 clinical testing?

Mecbotamab vedotin (BA3011) and ozuriftamab vedotin (BA3021) are currently in Phase 2 testing.